Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pharmaxis Ltd ( (AU:SNT) ) has provided an announcement.
Syntara Limited announced that the World Health Organization has granted the International Non-Proprietary Name (INN) of amsulostat to its clinical asset SNT-5505, marking a significant milestone in its development. Amsulostat, an oral therapy for myelofibrosis, has shown promising results in Phase 2 trials and is positioned as a differentiated treatment option for patients with suboptimal responses to existing therapies. This recognition enhances global communication and reflects the drug’s unique mechanism and clinical potential, further supported by its recent Fast Track Designation by the FDA.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company specializing in extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines targeting blood cancers and conditions related to inflammation and fibrosis. The company is advancing its lead candidate, amsulostat, for treating myelofibrosis and is involved in various collaborations for other therapeutic areas. Syntara is listed on the Australian Securities Exchange and is based in Sydney, Australia.
Average Trading Volume: 10,799,133
Technical Sentiment Signal: Sell
Current Market Cap: A$81.3M
For a thorough assessment of SNT stock, go to TipRanks’ Stock Analysis page.